SUPPLEMENTARY INFORMATION
10 min, 4C). For reticulocyte counts, blood was mixed in a 1:4 ratio with new methylene blue (EKI 7443) for 15 minutes and smears were made. More than 10 fields per mouse were acquired at 100X and at least 1000 RBCs were counted manually. Reticulocyte % was calculated as the average number of reticulocytes vs. total RBCs. Tissues were collected and tissue non-heme iron concentrations were determined as previously described 2 . Non-heme iron in Ficoll-purified RBCs was measured as previously described 3 . Iron levels in serum were determined using a kit as per manufacturer's instructions (Fisher Scientific/Pointe Scientific 23666320). Erythropoietin (Epo)
Histology. Tissues were processed as previously described 18 Å, ThermoFisher Scientific). Peptides were separated using a 3 hr gradient of 6-27% acetonitrile in 0.125% formic acid with a flow rate of 400 nL/min. Each analysis used an MS 3 -based TMT method as described previously 8 . The data were acquired using a mass range of m/z 350 -1350, resolution 120,000, AGC target 1 x 10 6 , maximum injection time 100 ms, dynamic exclusion of 120 seconds for the peptide measurements in the Orbitrap. Data dependent MS 2 spectra were acquired in the ion trap with a normalized collision energy (NCE) set at 35%, AGC target set to 1.8 x 10 4 and a maximum injection time of 120 ms. MS 3 scans were acquired in the Orbitrap with a HCD collision energy set to 55%, AGC target set to 1.5 x 10 5 , maximum injection time of 150 ms, resolution at 50,000 and with a maximum synchronous precursor selection (SPS) precursors set to 10. Mass spectra were processed using a Sequest-based in-house software pipeline as described previously 7 . Protein quantitation values were exported for further analysis. Each reporter ion channel was summed across all quantified proteins and normalized assuming equal protein loading of all nine samples.
Bioinformatic analysis
From all identified proteins only the ones with at least 2 peptides identified were subjected to further analysis. If splice variants of proteins were identified, we analyzed the one with the highest expression level. Proteins that were technical contaminants were excluded from the analysis.
Proteome data was log10-transformed before analysis in order to normalize distribution. Proteins differing between four groups were selected based on one-way analysis of variance (one-way ANOVA). FDRs were calculated for ANOVA p values using the Benjamini-Hochberg procedure.
Pairwise tests were performed for significant (p<0.05, FDR<0.05) peptides. Post-hoc pairwise comparisons (Bonferroni-adjusted t-test for 4 planned comparisons) were used to identify proteins with significant pairwise differences. Afterwards, gene set enrichment analyses were performed 9 .
This analysis searches for the locations of peptides associated with a given biological function or pathway within the ranked list of all peptides present in the dataset and calculates an enrichment score depending on the set being globally up-or down-regulated. GSEA has been successfully used for proteomic data 6 , and its reliance on validated and curated biological pathways made it a good tool for identifying processes dysregulated by Ncoa4 silencing. The canonical pathways
MSigDB geneset catalogue (c2.cp.v6.0.symbols.gmt) was selected for global gene set analysis.
Additionally, we selected pathways of interest (GO Hemoglobin complex, Hallmark Heme synthesis and Biocarta AHSP pathway) in order to validate the a priori hypothesis. NES were used in order to compare gene sets up-or downregulation status between different proteomic data.
Further we used a dataset from Gautier et al. 10 
Study approval
All animal studies were conducted in compliance with ethical regulations approved by the Dana-Farber Cancer Institute Institutional Animal Care and Use Committee (IACUC) under protocol number 15-020. 
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